{"id":"NCT02547441","sponsor":"Maruho Co., Ltd.","briefTitle":"Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle","officialTitle":"A Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle Administered for 12 Weeks to Subjects With Papulopustular Rosacea With an Open-Label Safety Extension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12","primaryCompletion":"2017-07-05","completion":"2018-04-13","firstPosted":"2015-09-11","resultsPosted":"2022-08-02","lastUpdate":"2022-08-02"},"enrollment":463,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rosacea"],"interventions":[{"type":"DRUG","name":"CLS001 (Omiganan)","otherNames":[]},{"type":"DRUG","name":"Vehicle","otherNames":[]}],"arms":[{"label":"Treatment","type":"EXPERIMENTAL"},{"label":"Vehicle Gel","type":"PLACEBO_COMPARATOR"}],"summary":"This study evaluates the safety and efficacy of once-daily application of CLS001 topical gel compared to vehicle gel in subjects with severe papulopustular rosacea.","primaryOutcome":{"measure":"Change in Inflammatory Lesion Count From Baseline to Week 12","timeFrame":"12 weeks","effectByArm":[{"arm":"Treatment","deltaMin":-18.1,"sd":1.77},{"arm":"Vehicle Gel","deltaMin":-13.5,"sd":1.85}],"pValues":[{"comp":"OG000 vs OG001","p":"0.043"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":41,"countries":["United States","Australia","Canada","France","Germany","Netherlands","New Zealand","Sweden","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":235},"commonTop":["Viral upper respiratory tract infection","Headache","Upper respiratory tract infection","Rosacea","Application site pain"]}}